Do you want to read an article? Please log in or register.
International Severe Asthma Registry: Mission Statement: The ISAR Study Group
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR)
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Chest.
Eileen W, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, Cho YS, Canonica GW, Heffler E, Gibson PG, Hew M, Peters M, Harvey ES, Alacqua M, Zangrilli J, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Hosseini N, Murray RB, Price DB
doi: 10.1016/j.chest.2019.10.053.
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
RECOMMENDED
Asthma
Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Thorax
Jackson DJ, Busby J, Pfeffer PE, Menzies-Gow A, Brown T, Gore R, Doherty M, Mansur AH, Message S, Niven R, Patel M, Heaney LG, UK Severe Asthma Registry.
doi: 10.1136/thoraxjnl-2020-215168
Asthma
Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study
Allergy Asthma Immunol Res.
Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M, Zhong N; China Omalizumab Study Group
doi: 10.4168/aair.2016.8.4.319.
Asthma
Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study
Lancet Respir Med.
Shrine N, Portelli MA, John C, Soler Artigas M, Bennett N, Hall R, Lewis J, Henry AP, Billington CK, Ahmad A, Packer RJ, Shaw D, Pogson ZEK, Fogarty A, McKeever TM, Singapuri A, Heaney LG, Mansur AH, Chaudhuri R, Thomson NC, Holloway JW, Lockett GA, Howarth PH, Djukanovic R, Hankinson J, Niven R, Simpson A, Chung KF, Sterk PJ, Blakey JD, Adcock IM, Hu S, Guo Y, Obeidat M, Sin DD, van den Berge M, Nickle DC, Bossé Y, Tobin MD, Hall IP, Brightling CE, Wain LV, Sayers I
doi: 10.1016/S2213-
Asthma
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
Adv Ther.
Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A
doi: 10.1007/
Asthma
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
J Asthma.
Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY
doi: 10.1080/02770903.
Asthma
A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels
Respir Med.
Haughney J, Morice A, Blyth KG, Lee AJ, Coutts A, McKnight E, Pavord I
doi: 10.1016/j.rmed.2017.12.001.
Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry.
Thorax.
Sweeney J, Patterson CC, Menzies-Gown A, Niven RM, Mansur AH, Bucknall C, Chaudhuri R, Price D, Brightling CE, Heaney LG on behalf of the British Thoracic Society Difficult Asthma Network
doi: 10.1136/